Block Listing Interim Review

Allergy Therapeutics PLC

17 December 2024

 

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Block Listing Interim Review

Name of applicant:		ALLERGY THERAPEUTICS PLC
Name of scheme:		Allergy Therapeutics plc 2013 Long Term Incentive Plan
Period of return:	From:	1 October 2023	To:	17 December 2024
Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission:		10,000,000 ordinary shares of 0.1p each in the Company admitted to trading on 24 November 2017 Additional listing of 7,000,000 ordinary shares of 0.1p each in the Company admitted to trading on 7 April 2021 Additional listing of 5,000,000 ordinary shares of 0.1p each in the Company admitted to trading on 3 October 2023
Balance of unallotted securities under scheme(s) from previous return:		12,013,147 ordinary shares
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
Less:  Number of securities issued/allotted under scheme(s) during period:		12,013,147 ordinary shares of 0.1p each
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		Nil

Name of contact:	Karley Cheesman
Telephone number of contact:	[phone]

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

[phone]

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker / Rory Sale

Nigel Birks - Life Science Specialist Sales

Tamar Cranford Smith - Sales

[phone]

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

[phone]

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. For more information, please see www.allergytherapeutics.com.

 

END